181 related articles for article (PubMed ID: 29222349)
21. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
[TBL] [Abstract][Full Text] [Related]
22. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
23. Peripheral Manifestations in Spondyloarthritis and their Effect: An Ancillary Analysis of the ASAS-COMOSPA Study.
López-Medina C; Moltó A; Dougados M
J Rheumatol; 2020 Feb; 47(2):211-217. PubMed ID: 30988127
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study.
Bautista-Molano W; Landewé R; Burgos-Vargas R; Maldonado-Cocco J; Moltó A; van den Bosch F; Valle-Oñate R; Dougados M; van der Heijde D
J Rheumatol; 2018 Feb; 45(2):206-212. PubMed ID: 29247152
[TBL] [Abstract][Full Text] [Related]
25. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
Sepriano A; Ramiro S; van der Heijde D; Ávila-Ribeiro P; Fonseca R; Borges J; Teixeira L; Carvalho PD; Cerqueira M; Neves J; Meirinhos T; Barcelos A; Sequeira G; Salvador MJ; Canas da Silva J; Santos H; Bernardes M; Vieira-Sousa E; Canhão H; Branco JC; Pimentel-Santos F; Landewé R
Arthritis Rheumatol; 2016 Nov; 68(11):2671-2679. PubMed ID: 27273894
[TBL] [Abstract][Full Text] [Related]
26. Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach.
Chimenti MS; Conigliaro P; Triggianese P; Canofari C; Cedola F; Onali S; Calabrese E; Romeo S; Neri B; De Cristofaro E; Biancone L; Perricone R
Clin Exp Rheumatol; 2019; 37(5):723-730. PubMed ID: 31172920
[TBL] [Abstract][Full Text] [Related]
27. Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.
Lee MP; Lii J; Jin Y; Desai RJ; Solomon DH; Merola JF; Kim SC
Arthritis Care Res (Hoboken); 2018 May; 70(5):791-796. PubMed ID: 28804988
[TBL] [Abstract][Full Text] [Related]
28. Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.
Canouï-Poitrine F; Poulain C; Molto A; Le Thuaut A; Lafon C; Farrenq V; Ferkal S; Le Corvoisier P; Ghaleh B; Bastuji-Garin S; Fautrel B; Dougados M; Claudepierre P
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1395-402. PubMed ID: 24664935
[TBL] [Abstract][Full Text] [Related]
29. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
30. Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: results of an international survey.
van der Heijde D; Sieper J; Elewaut D; Deodhar A; Pangan AL; Dorr AP
J Clin Rheumatol; 2014 Dec; 20(8):411-7. PubMed ID: 25417676
[TBL] [Abstract][Full Text] [Related]
31. The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis.
Spadaro A; Lubrano E; Marchesoni A; Cauli A; Cantini F; Carotti M; D'Angelo S; Grassi W; Lapadula G; Macchioni P; Mathieu A; Punzi L; Ramonda R; Salaffi F; Salvarani C; Scarpa R; Olivieri I
Clin Exp Rheumatol; 2014; 32(4):465-70. PubMed ID: 24850468
[TBL] [Abstract][Full Text] [Related]
32. Risk of cutaneous herpes zoster in patients with spondyloarthritis treated with conventional and biologic disease-modifying antirheumatic drugs.
Wong SCT; Li IWS; Ng AHY; Lau CS; Chung HY
Int J Rheum Dis; 2020 Feb; 23(2):189-196. PubMed ID: 31489783
[TBL] [Abstract][Full Text] [Related]
33. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
[TBL] [Abstract][Full Text] [Related]
35. Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database.
Tekgoz E; Colak S; Yardimci KG; Kucuksahin O; Cinar M; Yilmaz S; Kasifoglu T; Bes C; Yagiz B; Erden A; Kilic L; Kanitez NA; Ertenli AI; Coskun BN; Ediboglu ED; Mercan R; Kiraz S; Yazisiz V; Karadag O; Atagunduz P; Kalyoncu U
J Clin Rheumatol; 2022 Mar; 28(2):e318-e323. PubMed ID: 34014053
[TBL] [Abstract][Full Text] [Related]
36. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
37. The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward.
van der Linden S; Akkoc N; Brown MA; Robinson PC; Khan MA
Curr Rheumatol Rep; 2015 Sep; 17(9):62. PubMed ID: 26286179
[TBL] [Abstract][Full Text] [Related]
38. Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme.
Tomero E; Mulero J; de Miguel E; Fernández-Espartero C; Gobbo M; Descalzo MA; Collantes-Estévez E; Zarco P; Muñoz-Fernández S; Carmona L;
Rheumatology (Oxford); 2014 Feb; 53(2):353-60. PubMed ID: 24196385
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
[TBL] [Abstract][Full Text] [Related]
40. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
